Erectile Dysfunction

Erectile Dysfunction as a Harbinger of Cardiovascular Risk

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.^[1] It is a common condition in men, with prevalence increasing with age, and is often a marker of underlying vascular, neurological, or endocrine disease. For the Family Nurse Practitioner (FNP), ED is a high-yield exam topic because it requires a systematic approach to history, physical examination, risk stratification, and evidence-based management, while also providing an opportunity to screen for cardiovascular risk factors.^[2]

• Exam relevance: ED is frequently tested in FNP certification exams as a model for integrating psychosocial, medical, and pharmacological management.
• Clinical significance: ED can be an early warning sign for coronary artery disease (CAD) and should prompt evaluation of cardiovascular health.^[3]

Terminology for ED Classification

Important Terminology

• Erectile dysfunction (ED): Consistent difficulty with achieving or maintaining erection rigidity for completion of satisfactory sexual activity, lasting at least 3 months.^[1]
• Psychogenic ED: ED caused primarily by psychological factors (e.g., performance anxiety, depression, relationship stress).
• Organic ED: ED due to vascular, neurological, hormonal, or anatomical causes.
• Mixed ED: Combination of psychogenic and organic components – the most common presentation.
• Nocturnal penile tumescence (NPT): Spontaneous erections during REM sleep; preserved NPT suggests psychogenic rather than organic ED.
• Phosphodiesterase-5 (PDE5) inhibitors: First-line pharmacotherapy for ED; they enhance nitric oxide–mediated vasodilation in the corpus cavernosum.^[4]

Neurovascular and Endocrine Mechanisms of ED

Physiology of Erection

Erection requires an intact neurovascular axis: sexual stimulation triggers parasympathetic outflow (S2–S4), releasing nitric oxide (NO) in the penile vascular endothelium. NO activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP), which relaxes smooth muscle in the corpus cavernosum, allowing blood inflow and trapping of blood within the tunica albuginea.^[5]

Mechanisms of ED

1. Vascular: Atherosclerosis, hypertension, diabetes → endothelial dysfunction → reduced NO bioavailability.
2. Neurological: Spinal cord injury, multiple sclerosis, diabetic neuropathy → impaired neurotransmission.
3. Hormonal: Hypogonadism (low testosterone), hyperprolactinemia, thyroid disorders.
4. Psychogenic: Anxiety, depression, stress → increased sympathetic tone → smooth muscle contraction.
5. Iatrogenic: Medications (e.g., beta-blockers, SSRIs, diuretics), pelvic surgery, radiation.
6. Structural: Peyronie’s disease, priapism sequelae, penile trauma.

Clinical Presentation and Historical Clues in ED

• Chief complaint: “Inability to get or keep an erection” – must assess onset (sudden vs. gradual), duration, situational vs. global, and partner context.
• Key historical clues:
  • Preserved morning or nocturnal erections → favors psychogenic cause.
  • Complete loss of all erections → suggests organic cause.
  • Difficulty achieving vs. maintaining erection points to different pathophysiology (e.g., vascular insufficiency vs. venous leak).
• Associated symptoms: Decreased libido, gynecomastia, loss of facial/body hair (suggest hypogonadism); claudication or chest pain (suggest vascular disease).
• Red flags: Acute onset with back pain (consider spinal cord compression or cauda equina syndrome); penile curvature (Peyronie’s); sudden loss with saddle anesthesia (spinal emergency).

Standardized Assessment and Diagnostic Testing for ED

History and Screening

Use validated instruments such as the International Index of Erectile Function (IIEF-5) to quantify severity. In FNP exams, remember to assess cardiovascular risk (e.g., Framingham Risk Score) and screen for modifiable risk factors: smoking, obesity, sedentary lifestyle, alcohol/drug use.^[2]

Physical Examination

• Vital signs, BMI, waist circumference.
• Cardiovascular: femoral/pedal pulses, bruits (peripheral vascular disease).
• Genitourinary: testicular size, penile plaques, digital rectal exam (DRE) for prostate size/nodules.
• Neurologic: bulbocavernosus reflex, perineal sensation.

Laboratory and Additional Testing (Per AUA Guidelines^[1])

Note: Routine use of penile Doppler ultrasound or arteriography is reserved for complex cases (e.g., trauma, young men without risk factors) and is not first-line for typical FNP practice.^[1]

Evidence-Based Management of Erectile Dysfunction

First-Line: Lifestyle and Modifiable Risk Factors

• Weight loss (if overweight), regular aerobic exercise, smoking cessation, moderate alcohol intake.^[6]
• Optimize management of comorbid conditions (hypertension, diabetes, dyslipidemia, depression).
• Review medications: substitute if possible (e.g., switch from beta-blocker to CCB, or SSRIs to bupropion).

Pharmacologic Therapy: PDE5 Inhibitors

For men without contraindications, PDE5 inhibitors are the medical mainstay.^[4] They are not aphrodisiacs; they require sexual stimulation. Available agents:

Contraindications: Nitrates (any form) – absolute due to risk of profound hypotension; use with caution in men with severe LV outflow obstruction, hypotension, or recent history of stroke/MI.^[4] For men who cannot use PDE5 inhibitors (e.g., on nitrates), consider second-line options.

Second-Line and Advanced Therapies

• Intracavernosal injections: Alprostadil, papaverine, or combination – effective for most organic ED, but requires teaching and has risk of priapism.
• Intraurethral alprostadil: Less effective than injection but less invasive.
• Vacuum erection devices (VED): Non-pharmacologic option, especially in elderly or men with comorbidities.
• Penile prosthesis: Surgical option for refractory cases; considered when medical therapy fails or is contraindicated.
• Testosterone replacement therapy (TRT): Only if confirmed hypogonadism with low morning testosterone ^[7]; must monitor prostate and hematocrit. TRT alone may not fully restore erections; often combined with PDE5 inhibitor.

Psychosocial Interventions

• Counseling/sex therapy – especially for psychogenic or mixed ED.
• Partner involvement improves outcomes.
• Treat underlying depression or anxiety with agents that have less sexual side effects (e.g., bupropion, mirtazapine).

Safety Monitoring and Complication Prevention in ED Care

• Priapism: Prolonged erection (>4 hours) – a urologic emergency. Instruct men using PDE5 inhibitors or intracavernosal therapy to seek immediate care if erection lasts >4 hours to prevent permanent fibrosis and impotence.
• Cardiovascular risk: Sexual activity is equivalent to moderate exercise. Use the Princeton Consensus Conference guidelines to stratify risk: men with low cardiovascular risk (controlled hypertension, asymptomatic) can safely use PDE5 inhibitors; men with unstable angina, uncontrolled HF, recent MI (<6 weeks), or severe valvular disease should be stabilized before resuming sexual activity.^[8]
• Drug interactions: PDE5 inhibitors potentiate the hypotensive effect of alpha-blockers (e.g., tamsulosin). Advise patients to initiate PDE5 inhibitor at lowest dose and with proper timing (e.g., sildenafil 25 mg with stable alpha-blocker regimen).
• Non-arteritic anterior ischemic optic neuropathy (NAION): Rare but serious – vision loss; warn patients to stop PDE5 inhibitor and seek immediate evaluation if sudden vision loss occurs.

Clinical Pearls and Exam-Focused Strategies for ED

• ED as a harbinger of CAD: Remember that ED often precedes coronary events by 2–5 years. On exams, choose “assess cardiovascular risk” as part of the workup.
• PDE5 inhibitors and nitrates: This is a high-yield contraindication. Sildenafil was originally developed for hypertension/angina; never prescribe with nitrates.
• Tadalafil “daily” dosing: 2.5–5 mg daily is approved for ED, also for BPH; good for men who want spontaneity.
• Testosterone testing: Always draw morning total testosterone before initiating TRT; if low, confirm with repeat level.
• Psychogenic vs. organic ED: Sudden onset with preserved morning erections → psychogenic. Gradual onset, no morning erections → organic.
• Memory aid for PDE5 inhibitors: “The five S’s: Sildenafil, Tadalafil, Vardenafil, Avanafil – all start with different letters but end in -afil; they all increase cGMP.” (Not a perfect mnemonic, but helps recall the class.)
• First-line for most men: Lifestyle modification + PDE5 inhibitor + treat underlying conditions. For men who fail PDE5 inhibitors (despite proper use), consider referral to urology.

References

1. American Urological Association (AUA). Erectile Dysfunction: AUA Guideline (2018). https://www.auanet.org/documents/guidelines/ed%20website%20final.pdf
2. Lewis, S. M., Dirksen, S. R., Heitkemper, M. M., & Bucher, L. (2023). Lewis's Medical-Surgical Nursing: Assessment and Management of Clinical Problems (12th ed.). Elsevier. ISBN: 9780323789435. https://books.google.co.ke/books?id=owEyAgAAQBAJ
3. Thompson, I. M., Tangen, C. M., Goodman, P. J., et al. (2005). Erectile dysfunction and subsequent cardiovascular disease. JAMA, 294(23), 2996–3002. https://doi.org/10.1001/jama.294.23.2996
4. Goldstein, I., Burnett, A. L., Rosen, R. C., et al. (2019). The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sexual Medicine Reviews, 7(1), 115–128. https://doi.org/10.1016/j.sxmr.2018.06.003
5. Saenz de Tejada, I., & Goldstein, I. (1991). Physiology of erection and pathophysiology of impotence. British Journal of Urology, 68(3), 225–232. (https://pubmed.ncbi.nlm.nih.gov/1913074/)
6. Guay, A. T. (2007). ED2: erectile dysfunction = endothelial dysfunction. Endocrine Practice, 13(4), 372–380. https://pubmed.ncbi.nlm.nih.gov/17543729/
7. Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2018). Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. https://doi.org/10.1210/jc.2018-00229
8. Nehra, A., Jackson, G., Miner, M., et al. (2012). The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clinic Proceedings, 87(8), 766–778. https://doi.org/10.1016/j.mayocp.2012.06.015